| Objective: To observe the effect of Licartin and TACE in the treatment of primary liver cancer recurrence.Methods: A total of 36 patients with hepatocellular carcinoma, who underwent radical resection from July 2009 to May 2010 in The First Affiliated Hospital of Fujian Medical University, were randomly divided into two groups: Licartin treatment group(study group) and TACE treatment group(control group), compared the toxicity and disease-free survival.Results: In study group, the incidence ofâ… /â…¡fever/chills was lower than the control group (P=0.027); the incidence of nausea/vomiting and pain was also lower than the control group, but not statistically significant (P>0.05). Patients in both groups appear thrombocytopenia, in which TACE treatment group decreased 21.8% (P = 0.000), Licartin treatment group decreased 11.5% (P = 0.012) . After the TACE treatment, the average of TBIL increase 29.1% (P=0.016), the average of ALB decrease 7.7% (P=0.010),the average of AST decrease 6.4% (P=0.472); After the Licartin treatment, the average of TBIL increase 11.6% (P=0.396), the average of ALB decrease 5.8% (P=0.112),the average of AST decrease 23.5% (P=0.414), no significant liver toxicity was observed in Licartin treatment group. The study group's recurrence rate in 0.5 , 1 year and the total follow-up period were all lower than control group, but not statistically significant (P>0.05). The average tumor-free survival (14.962 months) longer than the TACE group (13.369 months), but not statistically significant ( P = 0.329).Conclusion: The effect of Licartin in the prevention of liver cancer recurrence after surgery is better than TACE, it is an ideal method of treatment with no significant liver toxicity.
|
PDF Full Text Request